Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration
Kymera Therapeutics announced the first participant has been dosed in the Phase 1 trial of KT-485, an oral IRAK4 degrader for immunological diseases. The dosing event triggered a $20 million milestone payment from partner Sanofi, which is leading development and commercialization for the program outside of oncology.
Key figures
- Drug Name
- KT-485 (SAR447971)
- Phase Of Trial
- Phase 1
- Milestone payment
- 20000000
- Potential milestones
- 975000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.